Evox Therapeutics Acquires Exosome AAV Technology and Intellectual Property

Utilizing our DeliverEX™ platform, we are engineering exosomes to deliver protein and nucleic acid-based therapeutics to treat life-threatening rare diseases. At Evox Therapeutics we are harnessing the natural targeting and delivery capabilities of exosomes to engineer an entirely novel class of biotherapeutics.

Article Date

This article is featured on another website.

Go to article
May 30, 2024

Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors

First-in-human trial will evaluate the safety, tolerability, payload delivery, and preliminary efficacy of ACTM-838 as a single agent in an open-label monotherapy dose escalation study Systemically administered ACTM-838 is designed to selectively accumulate in the tumor microenvironment to locally deliver two potent payloads, engineered versions of IL-15 and STING, to stimulate both innate and adaptive […]

May 30, 2024

Actym Therapeutics Announces IND Clearance for Phase 1 Clinical Trial Investigating Lead Program ACTM-838 in Patients with Solid Tumors

First-in-human trial will evaluate the safety, tolerability, payload delivery, and preliminary efficacy of ACTM-838 as a single agent in an open-label monotherapy dose escalation study Systemically administered ACTM-838 is designed to selectively accumulate in the tumor microenvironment to locally deliver two potent payloads, engineered versions of IL-15 and STING, to stimulate both innate and adaptive […]

June 4, 2024

Now Available: Myrtelle ASGCT Symposium Presentation

Myrtelle shared clinical trial updates and future directions for Oligodendrocyte targeting AAVs at the 27th Annual Meeting of the ASGCT.

June 4, 2024

Now Available: Myrtelle ASGCT Symposium Presentation

Myrtelle shared clinical trial updates and future directions for Oligodendrocyte targeting AAVs at the 27th Annual Meeting of the ASGCT.